Fate Therapeutics (FATE) Reports In-Line Q4 EPS

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.44), in-line with the analyst estimate of ($0.44). Revenue for the quarter came in at $1.86 million versus the consensus estimate of $1.58 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI